Review of Panitumumab: A Targeted Therapy

Winkeljohn, Debra

doi:10.1188/08.cjon.30-32

Cited by 6 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Panitumumab is a recombinant human monoclonal antibody [59]; therefore, the risk of an infusion reaction is minimized. Vectibix® is indicated as a single agent for the treatment of EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens [60-62].…”

Section: Monoclonal Antibody Therapiesmentioning

confidence: 99%

Recent Advances in Anti-Angiogenic Therapy of Cancer

2011

View full text Add to dashboard Cite

Since angiogenesis is critical for tumor growth and metastasis, anti-angiogenic treatment is a highly promising therapeutic approach. Thus, for over last couple of decades, there has been a robust activity aimed towards the discovery of angiogenesis inhibitors. More than forty anti-angiogenic drugs are being tested in clinical trials all over the world. This review discusses agents that have approved by the FDA and are currently in use for treating patients either as single-agents or in combination with other chemotherapeutic agents.

show abstract

Section: Monoclonal Antibody Therapiesmentioning

confidence: 99%

Recent Advances in Anti-Angiogenic Therapy of Cancer

2011

View full text Add to dashboard Cite

show abstract

“…In recent years, considerable attention has been paid to newer agents that focus on certain cell receptors known as target therapies for their ability to bind to specific receptors on cancer cells and inhibit cellular pathways, which may lead to apoptosis, or cell death [3,4]. The molecular targets for these new drugs are located on the cell surface, in intracellular signaling pathways, in the cell nucleus, and on tumor and peri-tumor cell vessels.…”

Section: Introductionmentioning

confidence: 99%

Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors

et al. 2010

View full text Add to dashboard Cite

Patients with cancer show variable levels of immunosuppression at the time of the presentation, and cytotoxic antineoplastic therapy is the primary contributor to the clinical immunodeficiency often observed during the course of the disease. In both hematological and solid tumors, this phenomenon is primarily related to the T-cell depletion associated with inhibition of dendritic cell ability to induce both primary and secondary T- and B-cell responses. Complete restoration of immunocompetence following antineoplastic therapy implicates the progressive recovery of various cell subpopulations, and it is a complex process that also depends on the type, the dose, the scheduling, and the associations of the employed drugs. In the era of target therapies, several antiangiogenic drugs are increasingly used in combination with standard chemotherapy in the treatment of advanced solid tumors. Their clinical efficacy has been recently related not only to the specific antiangiogenic properties but also to an indirect hypothetical effect on the host immune system. In the present work, we have reviewed the most recent information regarding (1) the capacity of standard antineoplastic therapy to induce and maintain an immunodeficiency in patients with solid tumors and (2) the influence of the antiangiogenic treatment in association with standard chemotherapy on lymphocyte and dendritic cell subsets and the possible resulting additional antitumor mechanism.

show abstract

“…Feet should not be soaked for a long time to prevent tissues from loosening. In some cases surgery cannot be avoided (Busam et al, 2001;Eaby, n. d.;EMA, 2011b;Moy & Goss, 2007;Pérez-Soler et al, 2005;Segaert & van Cutsem, 2005;Winkeljohn, 2008). Conventional modalities to treat acne should not be used.…”

Section: Side Effects Of Panitumumab 331 Skin Toxicitymentioning

confidence: 99%

“…Systemic antihistamines are more useful to cure itching. If rash is accompanied by superinfection, external use of either clindamycin or mupirocin, or internal use of tetracycline are to be considered (Eaby, n. d.;EMA, 2011b;Hoda et al, 2008;Lacouture, 2009;Lacouture et al, 2010;Melosky et al, 2009;Moy & Goss, 2007;Peeters et al, 2008;Pérez-Soler et al, 2005;Pikó, 2009;Potthoff et al, 2011;Saif & Cohenuram, 2006;Winkeljohn, 2008). Efforts to deal with skin toxicities via pre-emptive approach (i.e.…”

Section: Side Effects Of Panitumumab 331 Skin Toxicitymentioning

confidence: 99%